Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3401016 in Alport Syndrome
NCT07211685Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in Alport syndrome comparing BAY 3401016 with Placebo (2 arms). Primary endpoint: Urinary albumin creatinine ratio at 24 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
BAY 3401016
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT07211685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211685.